Aquatic Capital Management LLC Purchases New Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Aquatic Capital Management LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 19,431 shares of the company's stock, valued at approximately $782,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Blue Trust Inc. lifted its holdings in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares during the last quarter. KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after acquiring an additional 752 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Kymera Therapeutics by 95.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock valued at $194,000 after acquiring an additional 2,350 shares in the last quarter. Summit Investment Advisors Inc. increased its position in Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after acquiring an additional 406 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Kymera Therapeutics in the 4th quarter worth about $251,000.

Wall Street Analyst Weigh In

Several research analysts have recently commented on KYMR shares. HC Wainwright raised their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, Citigroup assumed coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $56.36.

Kymera Therapeutics Price Performance

KYMR stock traded down $1.11 during midday trading on Tuesday, reaching $32.47. 257,912 shares of the stock were exchanged, compared to its average volume of 556,477. The company has a fifty day moving average price of $29.64 and a 200 day moving average price of $38.03. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The stock has a market capitalization of $2.11 billion, a PE ratio of -13.93 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at $2,064,510. The trade was a 2.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock worth $324,567 in the last quarter. 15.82% of the stock is owned by corporate insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.